Intravitreal dexamethasone implant-based versus ranibizumab-based regimens for stage 3 Coats' disease: Efficacy and complications.
Zhang Juan J, Zhang Meng M, Yang Qian Q, Chang Qing Q et al.
To compare the efficacy of intravitreal dexamethasone (DEX) implant-based regimen versus ranibizumab-based regimen for managing retinal exudation and complications in stage 3 Coats' disease. Thirty-seven eyes with stage 3 Coats' disease were enrolled and followed for 24 months: 16 received DEX implants and 21 received ranibizumab as initial treatments. Outcomes included changes in retinal exudation clocks and central foveal thickness (CFT), exudative retinal detachment (ERD) resolution, changes in best-corrected visual acuity (BCVA) and complications. The DEX implant reduced retinal exudation clocks and CFT more effectively than ranibizumab at 1, 2 and 3 months (all p < 0.05). Significantly more eyes in the DEX implant group achieved exudate absorption and complete ERD resolution within 12 months without additional surgeries (both p < 0.05). The BCVA improvement was superior in the DEX implant group than in the ranibizumab group (87.5% vs. 14.29%, p < 0.001). Elevated intraocular pressure occurred in 25.0% of DEX-treated eyes and was managed medically. Cataract surgery rates were higher in the DEX group at 12 months but comparable at 24 months. Tractional retinal detachment (TRD) and epiretinal membrane (ERM) occurred more frequently in the ranibizumab group (p = 0.003 and 0.017, respectively), and more eyes in the ranibizumab group needed additional pars plana vitrectomy by 24 months. The DEX implant group achieved superior anatomic and functional outcomes compared with the ranibizumab group for stage 3 Coats' disease, with fewer vision-threatening complications such as TRD and ERM. The DEX implant may be a promising adjuvant therapy for stage 3 Coats' disease.